Catalin Toma named chief medical officer at Jupiter Endovascular. New recruit is an associate professor of Medicine at the University of Pittsburgh School of Medicine. October 29, 2026 Managing Editor, Rodman Media Jupiter Endovascular Inc. has appointed renowned interventional cardiologist Catalin Toma, M.D., as chief medical officer. "Dr. Toma is a globally recognized physician, researcher and leader in interventional cardiovascular medicine," Jupiter Endovascular CEO Carl J. St. Bernard said. "His experience treating patients with complex pulmonary vascular and structural heart disease, combined with his deep understanding of the clinical evidence required to advance new therapies, will be invaluable as we realize the potential of our TFX platform. We are delighted to welcome him as our chief medical officer." Dr. Toma brings extensive clinical and research experience in the structural heart and interventional sectors to his new role at Jupiter Endovascular. He serves concomitantly as director of Interventional Cardiology for the University of Pittsburgh Medical Center (UPMC) Heart and Vascular Institute, is an associate professor of Medicine at the University of Pittsburgh School of Medicine, and leads the Chronic Total Occlusion Program at UPMC Presbyterian Hospital. He has served as co-principal investigator for a clinical study of the company's Vertex Thrombectomy System for pulmonary embolism, as well as for many other high-profile clinical trials in the interventional space, including leading pulmonary embolism systems and transcatheter heart valves. He has published extensively and holds several invention patents. "Jupiter Endovascular is addressing a long-standing challenge in cardiovascular intervention, which is balancing the competing needs of flexibility and stability in your catheters without creating cardiac distress in unstable patients," Dr. Toma stated. "I have seen the capabilities of the company's TFX technology in the Vertex System that enables one catheter to change its state from flexible to fixed, and back again, firsthand in the SPIRARE II trial, and am very encouraged about its potential to enable us to do more than we can today with current commercial technologies. I'm also energized by the company's vision to look beyond clot removal to the restoration of patient hemodynamics and right-heart recovery with the intent to improve long-term prospects for PE patients." The Vertex Thrombectomy System leverages Jupiter Endovascular's proprietary Transforming Fixation (TFX) platform technology to navigate flexibly through the right heart and transform into a stabilized state in the pulmonary arteries for precise, controlled intervention. TFX's ability to decouple flexible navigation from stable support addresses longstanding challenges in pulmonary embolism thrombectomy related to cardiac strain, guidewire reliance, and reliable vessel access - enabling the system to achieve afterload relief and hemodynamic recovery alongside clot removal. Jupiter Endovascular Inc. is a Menlo Park, Calif.-based medical technology company developing a new class of endovascular interventions using its proprietary TFX technology. The company's Vertex Thrombectomy System provides physicians with on-demand stability and control during transcatheter intervention in the pulmonary vasculature. Add Mpo Mag as a preferred source on Google. Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Jupiter Endovascular appoints catalin Toma, MD, as Chief Medical Officer. More in financial: MENLO PARK, Calif.-(BUSINESS WIRE)- #TFX-Jupiter Endovascular appoints renowned interventional cardiologist Dr. Catalin Toma as Chief Medical Officer See full post here as originally published on this site